PALO ALTO, Calif., July 12, 2021 /PRNewswire/ -- BridgeBio Pharma,
Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver meaningful medicines
for patients with genetic diseases and cancers with clear genetic
drivers, today announced that on July 1,
2021, the compensation committee of BridgeBio's board of
directors granted 20 new employees restricted stock units for an
aggregate of 26,761 shares of the Company's common stock. All of
the above-described awards were made under BridgeBio's 2019
Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by
BridgeBio's board of directors in November 2019.
About BridgeBio
BridgeBio is a biopharmaceutical company founded to discover,
create, test and deliver transformative medicines to treat patients
who suffer from genetic diseases and cancers with clear genetic
drivers. BridgeBio's pipeline of over 30 development programs
ranges from early science to advanced clinical trials and its
commercial organization is focused on delivering the Company's
first approved therapy. BridgeBio was founded in 2015 and its team
of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information visit
bridgebio.com.
Media Contact:
Grace
Rauh
Grace.rauh@bridgebio.com
(917) 232-5478
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301331891.html
SOURCE BridgeBio